What Helios CORP. maintains is a core group of ingredients in specific market segments that have the ability to transform individual health paradigms, worldwide.

  Our performance data is exceptional and each and every one of our clinical studies is a potential “game changer” for the benefit of the consumer. We are certain there are no other companies providing the level of science that we provide with all of our listed ingredients.

 June 19th, 2011
Helios and their partner, Sunbio, recently recieved the Top Innovation and Technology Award for NC-518 at the 2011 National IFT which was held in New Orleans in June. NC-518 maintains a Phase I and a USA based Phase II, placebo controlled, randomized, double blind, human clinical study. NC-518 increased bone density in the active group by 2.2% over 4 months. As nutritional ingredient, NC-518 is now gaining significant interest in the Beverage and Dairy categories.


July 11th, 2011
Helios and their partner, Sunbio Corp, received Health Canada (NHPD) license certification for their branded ingredient called EstroG-100. This allows Canadian mfg. partners to use EstroG-100 in finished products and make up to ten end point claims concerning menopausal symptoms. EstroG-100 significantly improved 10 of 12 end points in their USA based Phase II human clinical study when utilizing the test model called the Kupperman Index. With the NHPD license and EstroG-100's NDI application and subsequent no objection letter from FDA, the USA, Mexico and Canadian customers can now receive the full benefits of EstroG-100 managing ten menopausal symptoms.

March 10, 2012

At the 2012 Engredea, Expo West Convention in Anaheim, CA Helios CORP was awarded the distinction as the " TOP Science Company" at the show. This was related to our continued effort to provide end use manufacturers with Nutra ingredient choices that are backed by human Phase I and human Phase II clinical studies. The benefit is that our customers have validated science backed to our Nutra ingredients which provides them the opportunity to make stronger or better structure function claims on their finished product labels.



 February 22, 2013

Helios CORP was chosen by the highly respected publication, Nutrition Industry Excutive, as the Supplier of the Month in the Jan/ Feb 2013 issue, page 19. We are grateful for the acknowledgement and story that outlines Helios CORP's commitment to science first, and also our commitment to clinical studies utilizing the Gold Medal Standards when evaluating performance, safety, and efficacy.


 PAGE 19






  Helios CORP. is a nutritional, science based organization. Our team is highly trained to translate cultural remedies into prospective commercial ingredients. The process per ingredient will take three years to develop. This includes the
remedy derived from written text of a plant, fruit, or mineral.

  Then we evaluate the effectiveness of the remedy in human Phase I, and human Phase II clinical studies. The end user will convert this ingredient into finished form and then market the benefit of strong label claims based on the efficacy, safety, and performance from our clinical